PC
RARE icon

Pier Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

Pier Capital’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-125,728
Closed -$5.83M – 122
2017
Q4 		$5.83M Buy
+125,728
New +$6.16M 1% 50

Other funds holding RARE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Pier Capital's RARE Position: Q1 2018 in Review

Pier Capital sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2018, closing a stake of 125,728 shares — an estimated $5.83M sold.

Pier Capital first reported a position in RARE in Q4 2017 and held it in 1 quarter. The position peaked at $5.83M in Q4 2017. 165 funds tracked by Wall St. Rank hold RARE as of Q1 2018.

  • Pier Capital reported no remaining Ultragenyx Pharmaceutical position as of Q1 2018 after selling out during the quarter.
  • Pier Capital sold 125,728 Ultragenyx Pharmaceutical shares in Q1 2018, an estimated $5.83M.
  • Pier Capital first reported a position in Ultragenyx Pharmaceutical in Q4 2017 and held it in 1 quarter.
  • Pier Capital's Ultragenyx Pharmaceutical position peaked at $5.83M in Q4 2017.
  • 165 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2018.

Based on Pier Capital's 13F filing for Q1 2018, filed 14 May 2018.